- Companies
- Distalmotion
Distalmotion Funding, Investors & Competitors
Distalmotion has raised $391M across 5 funding rounds, most recently a strategic investment round in January 2026.
Last Distalmotion funding round
Strategic investment
Amount undisclosed · Jan 2026
Cumulative funding Distalmotion raised
$391M
across 5 funding rounds
Key investors in Distalmotion
Revival Healthcare Capital
Johnson & Johnson Innovation
415 Capital
Swiss Entrepreneurs Foundation
About Distalmotion
Distalmotion is a Lausanne-headquartered medical device company developing the Dexter surgical robot for general surgery, gynecology, and urology. The Swiss-designed system merges laparoscopy affordability with robotic precision through on-demand functionality.
Founded
2012
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Product sales
Distalmotion Funding History
Distalmotion has raised a total of $391M across 5 funding rounds.
Distalmotion's first fundraising round was a $90M Series E in January 2022. The most recent completed round was a strategic investment round in January 2026.
Distalmotion funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Jan 2026 | Strategic investment | Johnson & Johnson Innovation (lead) | - | Distalmotion, a Lausanne, Switzerland-based MedTech company, develops the DEXTER robotic surgery system for minimally invasive procedures in general surgery, gynecology, and urology, with a focus on ambulatory surgery centers (ASCs). DEXTER features a small, mobile footprint, flexible workflows, open architecture, and instinctive design, and holds U.S. clearance for inguinal hernia repair, cholecystectomy, and benign hysterectomy. The system has treated over 3,000 patients across Europe and the United States. In January 2026, Distalmotion secured a strategic investment from Johnson & Johnson Innovation – JJDC, Inc., following its $150 million Series G round in 2025 led by Revival Healthcare Capital. The investment supports expansion of DEXTER into ASCs, the fastest-growing U.S. site of care segment, driven by patient preferences for convenience, quality, and cost-effective outpatient procedures. ASCs seek soft tissue robotics to aid surgeon recruitment, patient attraction, and consistent minimally invasive care. This backing highlights growing demand for adaptable robotic platforms in outpatient settings, positioning Distalmotion to compete amid shifts from hospitals, with DEXTER designed for ASC efficiency and integration with existing medical technology. |
| Nov 2025 | Series G | Revival Healthcare Capital (lead) | $150M | Distalmotion, a Lausanne, Switzerland-based MedTech company, develops the DEXTER robotic surgery system designed to simplify operations and broaden access to robotic-assisted minimally invasive surgery in various sites of care, including hospital outpatient departments (HOPDs) and ambulatory surgery centers (ASCs). DEXTER features wristed, one-time-use instruments for enhanced precision and dexterity, is easily movable and quick to set up, and is commercially available in the US and Europe, with nearly 3,000 patients treated across these regions. On November 18, 2025, Distalmotion closed a $150 million USD Series G financing round led by Revival Healthcare Capital, with participation from existing inside investors. The funds are earmarked primarily to accelerate US commercial adoption of DEXTER, particularly targeting the fast-growing ASC market driven by shifts toward efficient outpatient procedures, as well as to support ongoing clinical programs and product development. This milestone validates the company's vision to reduce barriers to robotic surgery access. In tandem with the financing, Distalmotion appointed Chas McKhann as Executive Chairman, bringing over 25 years of MedTech experience from leading Apollo Endosurgery and Silk Road Medical to successful exits. Recent advancements include FDA clearance in gynecology and DEXTER product enhancements, positioning the company for accelerated growth in the US and globally. The investment underscores strong clinical traction and strategic focus on ASCs amid rising demand for robotics in outpatient settings. |
| Jul 2024 | Undisclosed stage | Swiss Entrepreneurs Foundation (lead) | - | The Swiss Entrepreneurs Fund made a direct investment in Distalmotion, the Lausanne maker of robot-assisted surgical systems, to support commercialisation of its Dexter platform after the development phase. The fund is a FINMA-regulated CHF 250 million vehicle that writes CHF 5 million to CHF 20 million tickets into Swiss companies in their growth phase, with direct investments managed alongside its partner Helvetica Capital. The round type and amount were not disclosed. |
| Apr 2023 | Series F | Revival Healthcare Capital (lead) | $151M | Distalmotion is a Switzerland-based MedTech company developing the DEXTER robotic surgery system, designed for minimally invasive procedures in general surgery, gynecology, and urology. DEXTER enables on-demand robotics, allowing surgeons to switch between robotic and laparoscopic modes, and is mobile for easy integration across hospital departments and surgery centers without additional infrastructure. As of April 19, 2023, Distalmotion announced the first closing of a USD 150 million financing led by Revival Healthcare Capital with participation from existing investors, aimed at accelerating FDA approval and expanding clinical use in Europe and the US. Subsequent developments include a Series G round of $150M also led by Revival in November 2025 for US expansion into ambulatory surgery centers (ASCs), appointment of Chas McKhann as Executive Chairman, FDA clearance in gynecology, and a strategic investment from Johnson & Johnson Innovation – JJDC in January 2026, with over 3,000 patients treated across Europe and the US. |
| Jan 2022 | Series E | Revival Healthcare Capital (lead); 415 Capital | $90M | Distalmotion, a Swiss MedTech company, develops the Dexter surgical robot, a user-centric system for laparoscopic surgery that integrates proven workflows, keeps surgeons in the sterile field, and supports minimally invasive procedures. On January 26, 2022, it closed a USD 90 million Series E financing round led by Revival Healthcare Capital, with participation from 415 Capital and existing investors, to accelerate global commercialization following Dexter’s initial clinical use, support procedure guidelines, training protocols via European hospitals and an Early Adopter Program, and prepare a U.S. FDA submission. Revival provided hands-on leadership, with Chairman Rick Anderson joining Distalmotion’s board as Chairman and President Lauren Forshey as an observer. Dexter, CE-marked at the time, shifts robotic surgery paradigms by emphasizing surgeon control and direct patient access, aiming to make robotic assistance more accessible and efficient compared to traditional systems. The financing backed international scaling, with early clinical cases performed, including the world’s first general surgery by Prof. Dieter Hahnloser at Lausanne University Hospital. Later developments include a $150 million Series G round in November 2025, again led by Revival Healthcare Capital, to drive U.S. expansion of Dexter, focusing on Ambulatory Surgery Centers, clinical programs, and product enhancements post-FDA clearance in gynecology. By late 2025, Dexter treated nearly 3,000 patients across Europe and the U.S., with Greg Roche as CEO and Chas McKhann appointed Executive Chairman. A subsequent strategic investment followed the Series G, emphasizing ASC growth amid shifts to outpatient surgery. |
Who has invested in Distalmotion?
4 investors have backed Distalmotion across its funding rounds, including Revival Healthcare Capital, Johnson & Johnson Innovation, 415 Capital and Swiss Entrepreneurs Foundation.
Lead investors include Johnson & Johnson Innovation, Revival Healthcare Capital and Swiss Entrepreneurs Foundation.
Distalmotion Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 3 | Lead | Jan 2022 | ||
| 1 | Lead | Jul 2024 | ||
This data is available for Pro users. Sign up to see all 4 Distalmotion investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialDistalmotion Competitors
Distalmotion competitors include listed companies like Siemens, Johnson & Johnson, Roche and Thermo Fisher Scientific, and private ones like Biosplice Therapeutics and Neuralink.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $91B | $15B | $234B | 2.9x | ||
| Publicly listed | $94B | $40B | $651B | 6.8x | ||
| Publicly listed | $77B | $26B | $351B | 4.9x | ||
| Publicly listed | $45B | $11B | $243B | 6.0x | ||
| Private | - | - | $12B | - | ||
| Private | - | - | $9B | - |
Distalmotion Public Comps
Distalmotion is still privately-owned, but its public comps include Samsung, Johnson & Johnson, Roche, Thermo Fisher Scientific, Siemens, Schneider Electric, Abbott, ABB, Hitachi and Danaher.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $243B | $67B | 4.4x | 2.4x | 15.8x | 4.4x | |||
| $94B | $40B | 7.2x | 6.8x | 17.0x | 18.3x | |||
| $77B | $26B | 5.0x | 4.9x | 14.6x | 12.4x | |||
| $45B | $11B | 6.3x | 6.0x | 26.8x | 23.6x | |||
| $91B | $15B | 3.0x | 2.9x | 18.1x | 15.7x | |||
| $46B | $9.5B | 4.3x | 3.9x | 21.0x | 18.4x | |||
| $44B | $12B | 4.6x | 4.2x | 17.4x | 15.8x | |||
| $33B | $6.9B | 5.4x | 4.9x | 25.9x | 22.6x | |||
This data is available for Pro users. Sign up to see all Distalmotion competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Distalmotion
| When was Distalmotion founded? | Distalmotion was founded in 2012. |
| Where is Distalmotion headquartered? | Distalmotion is headquartered in Lausanne, Switzerland. |
| Is Distalmotion publicly listed? | No, Distalmotion is a private, VC-backed company. |
| How much funding has Distalmotion raised? | Distalmotion has raised $391M across 5 funding rounds. |
| What was Distalmotion's last funding round? | Distalmotion's last funding round was a strategic investment round in January 2026, led by Johnson & Johnson Innovation. |
| Who are Distalmotion's investors? | Distalmotion's investors include Revival Healthcare Capital, Swiss Entrepreneurs Foundation, Johnson & Johnson Innovation and 415 Capital. |
| Which companies are comparable to Distalmotion? | Companies comparable to Distalmotion include Siemens, Johnson & Johnson, Roche, Thermo Fisher Scientific, Biosplice Therapeutics and Neuralink. |
See companies similar to Distalmotion
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




